Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
14 02 2023
14 02 2023
Historique:
received:
23
12
2022
accepted:
07
02
2023
entrez:
14
2
2023
pubmed:
15
2
2023
medline:
17
2
2023
Statut:
epublish
Résumé
Convergent evolution of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 lineages has led to the emergence of several new subvariants, including BA.2.75.2, BA.4.6. and BQ.1.1. The subvariant BQ.1.1 became predominant in many countries in December 2022. The subvariants carry an additional and often redundant set of mutations in the spike, likely responsible for increased transmissibility and immune evasion. Here, we established a viral amplification procedure to easily isolate Omicron strains. We examined their sensitivity to 6 therapeutic monoclonal antibodies (mAbs) and to 72 sera from Pfizer BNT162b2-vaccinated individuals, with or without BA.1/BA.2 or BA.5 breakthrough infection. Ronapreve (Casirivimab and Imdevimab) and Evusheld (Cilgavimab and Tixagevimab) lose antiviral efficacy against BA.2.75.2 and BQ.1.1, whereas Xevudy (Sotrovimab) remaine weakly active. BQ.1.1 is also resistant to Bebtelovimab. Neutralizing titers in triply vaccinated individuals are low to undetectable against BQ.1.1 and BA.2.75.2, 4 months after boosting. A BA.1/BA.2 breakthrough infection increases these titers, which remains about 18-fold lower against BA.2.75.2 and BQ.1.1, than against BA.1. Reciprocally, a BA.5 breakthrough infection increases more efficiently neutralization against BA.5 and BQ.1.1 than against BA.2.75.2. Thus, the evolution trajectory of novel Omicron subvariants facilitates their spread in immunized populations and raises concerns about the efficacy of most available mAbs.
Identifiants
pubmed: 36788246
doi: 10.1038/s41467-023-36561-6
pii: 10.1038/s41467-023-36561-6
pmc: PMC9926440
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Antiviral Agents
0
BNT162 Vaccine
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
824Subventions
Organisme : NIAID NIH HHS
ID : U01 AI151758
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2023. The Author(s).
Références
Cell Rep Med. 2022 Dec 20;3(12):100850
pubmed: 36450283
N Engl J Med. 2023 Feb 9;388(6):565-567
pubmed: 36630611
J Gen Virol. 2020 Sep;101(9):925-940
pubmed: 32568027
Nat Med. 2022 Aug;28(8):1715-1722
pubmed: 35710987
Cell Host Microbe. 2022 Nov 9;30(11):1540-1555.e15
pubmed: 36272413
N Engl J Med. 2022 May 12;386(19):1804-1816
pubmed: 35263534
Nature. 2022 Mar;603(7902):700-705
pubmed: 35104835
N Engl J Med. 2022 Nov 17;387(20):1904-1906
pubmed: 36260835
Lancet Infect Dis. 2022 Sep;22(9):1278
pubmed: 35863364
N Engl J Med. 2021 Sep 23;385(13):1184-1195
pubmed: 34347950
Lancet Infect Dis. 2022 Dec;22(12):1666-1668
pubmed: 36328002
N Engl J Med. 2022 Jul 7;387(1):86-88
pubmed: 35731894
N Engl J Med. 2022 Jun 9;386(23):2188-2200
pubmed: 35443106
Nat Med. 2022 Jun;28(6):1297-1302
pubmed: 35322239
Trends Immunol. 2021 Nov;42(11):956-959
pubmed: 34580004
Nature. 2023 Feb;614(7948):521-529
pubmed: 36535326
Cell. 2022 Jul 7;185(14):2422-2433.e13
pubmed: 35772405
N Engl J Med. 2023 Jan 12;388(2):183-185
pubmed: 36546661
Lancet. 2022 Feb 12;399(10325):625-626
pubmed: 35063123
Nat Rev Immunol. 2021 Jun;21(6):382-393
pubmed: 33875867
Cell. 2022 Nov 10;185(23):4333-4346.e14
pubmed: 36257313
Nat Microbiol. 2020 Oct;5(10):1185-1191
pubmed: 32908214
Cell Host Microbe. 2023 Jan 11;31(1):9-17.e3
pubmed: 36476380
Cancer Res. 1985 Oct;45(10):4970-9
pubmed: 3861241
Cell Rep. 2022 May 17;39(7):110812
pubmed: 35568025
J Infect. 2022 Oct;85(4):e104-e108
pubmed: 35803386
Lancet Infect Dis. 2022 Nov;22(11):1538-1540
pubmed: 36244347
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Cell. 2023 Jan 19;186(2):279-286.e8
pubmed: 36580913
Science. 2022 Nov 11;378(6620):619-627
pubmed: 36264829
Lancet. 2023 Dec 17;400(10369):2193-2196
pubmed: 36209762
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Nature. 2022 Feb;602(7898):682-688
pubmed: 35016197
Nature. 2022 Mar;603(7902):706-714
pubmed: 35104837
Nature. 2022 Aug;608(7923):593-602
pubmed: 35714668
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
N Engl J Med. 2023 Feb 9;388(6):567-569
pubmed: 36630643
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Nat Med. 2022 Sep;28(9):1785-1790
pubmed: 35760080
Lancet Infect Dis. 2022 Nov;22(11):1537-1538
pubmed: 36116462
Nat Med. 2023 Jan;29(1):247-257
pubmed: 36265510
Med (N Y). 2022 Dec 9;3(12):838-847.e3
pubmed: 36228619
Immunity. 2022 Jun 14;55(6):925-944
pubmed: 35623355
N Engl J Med. 2021 Nov 18;385(21):1941-1950
pubmed: 34706189
Science. 2022 May 6;376(6593):eabn4947
pubmed: 35289632
Cell Host Microbe. 2022 Nov 9;30(11):1527-1539.e5
pubmed: 36270286
Nat Med. 2021 May;27(5):917-924
pubmed: 33772244
Nat Med. 2022 Jul;28(7):1491-1500
pubmed: 35395151
Sci Transl Med. 2022 Aug 24;14(659):eabo7081
pubmed: 35638937
Cell. 2022 Mar 3;185(5):872-880.e3
pubmed: 35123650
Cell. 2022 Oct 13;185(21):3992-4007.e16
pubmed: 36198317
Nat Med. 2022 Nov;28(11):2388-2397
pubmed: 36202997
Lancet. 2022 Jan 29;399(10323):417-419
pubmed: 35065006
DNA Res. 2014 Dec;21(6):673-83
pubmed: 25267831
N Engl J Med. 2023 Feb 16;388(7):662-664
pubmed: 36652339
EMBO J. 2020 Dec 1;39(23):e106267
pubmed: 33051876
Sci Transl Med. 2022 Jul 27;14(655):eabn3715
pubmed: 35895836
Science. 2022 Jul 15;377(6603):eabq1841
pubmed: 35699621
EBioMedicine. 2021 Nov;73:103637
pubmed: 34678613
Nat Med. 2022 Dec 6;:
pubmed: 36473500
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326